On Topic Virtual Roundtable: “BTK Battle” " Experts Compare and Contrast the Latest Data of BTK Inhibitors for the Treatment of Hematologic Malignancies

Program Overview
This online roundtable discussion will focus on the use of BTK in patients with CLL/SLL, lymphoma, and other hematologic malignancies, as well as expert guidance in the selection and sequencing of this class of agents safely and effectively.

Target Audience
The target audience for this activity is community and academic medical oncologists, pulmonologists, allied health professionals, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Evaluate the safety and efficacy of currently approved BTK inhibitors for patients with hematologic malignancies, including CLL/SLL, lymphoma, and Waldenström’s macroglobulinemia
Review clinical trial results of emerging BTK-inhibitor-based strategies that are being investigated in patients with hematologic malignancies
Compare and contrast the safety and efficacy of BTK inhibitors in order to properly select and sequence this class of agents in patients with newly diagnosed and relapsed/refractory hematologic malignancies